Analyst Profile

Followed by 2,034 followers
.
Liana Moussatos

Liana Moussatos

Wedbush
Wall Street Analyst
#8,012 out of 8,160 Wall Street Analysts
#23,859 out of 24,427 experts

Success Rate

31%
98 out of 320 transactions made a profit

Average Return

-11.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Liana Moussatos's trades since 2009 and holding each position for 1 Year would result in 30.63% of your transactions generating a profit, with an average return of -11.1% per rating.

Stock Rating Distribution

2KRatings
88.37% Buy
11.27% Hold
0.36% Sell
Distribution of Liana Moussatos's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Lexicon Pharmaceuticals
(LXRX)
Rating:Buy
Date:Nov 03, 2020 - Jan 29, 2021
Return:+619.00%
The most profitable rating made by Liana Moussatos

Liana Moussatos's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
MDCO
Medicines Co
May 13, 2009
Buy
Upgraded
1Ratings
0.00%
AGN
Allergan
Mar 01, 2013
Hold
Downgraded
1Ratings
0.00%
MAPP
Map Pharmaceuticals
Mar 01, 2013
Hold
Downgraded
1Ratings
0.00%
~PATH
Nupathe Inc
Jan 22, 2014
Hold
Downgraded
1Ratings
0.00%
CHTP
Chelsea Therapeutics
Jun 23, 2014
Hold
Downgraded
6Ratings
0.00%
LJPC
La Jolla Pharma
Oct 23, 2014
Buy
Reiterated
$45.00
(623.47% Upside)
8Ratings
0.00%
TBRA
Tobira Therapeutics
Feb 19, 2015
Sell
Reiterated
5Ratings
0.00%
RCPT
Receptos
Aug 25, 2015
Hold
Downgraded
19Ratings
0.00%
KalVista Pharmaceuticals
Feb 29, 2016
Buy
Reiterated
$0.76
(-85.87% Downside)
8Ratings
0.00%
Cardiff Oncology
Mar 11, 2016
Buy
Reiterated
$60.00
(3721.66% Upside)
2Ratings
0.00%
List of latest recommendations made by Liana Moussatos. Click to expand and see Liana Moussatos's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >